

11-24-03

SP:-1631

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Alsobrook, et al.

**EXAMINER:** James Martinell

SERIAL NUMBER: 10/037,417

ART UNIT: 1631

FILING: DATE:

January 4, 2002

FOR:

HUMAN PROTEINS AND NUCLEIC ACIDS ENCODING

**Mail Stop IDS** 

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

#### TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (2 pages) in duplicate;
- 3. Copies of Cited references B1- B3, and C163-C172 and;
- 4. Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully resquested to contact the undersigned at (203) 974-6303, New Haven, Connecticut.

Respectfully submitted

Date: November 21, 2003

George Vahwak, Reg. No. 26,824

c/o Curaden Corporation

\$55 Long Wharf Drive New Haven, CT 06511

Tel: (203) 974-6303 Fax: (203) 401-3351



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Alsobrook, et al.

**EXAMINER:** James Martinell

SERIAL NUMBER: 10/037,417

ART UNIT: 1631

FILING DATE:

January 4, 2002

FOR:

**HUMAN PROTEINS AND NUCLEIC ACIDS ENCODING** 

Mail Stop IDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R.§§1.56, 1.97 and 1.98, Applicants hereby make of record the documents attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed with in three months of the mailing date of the International Report of PCT/US/02/00375. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, or that more relevant information does not exist; and (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R.§ 1.56(b).

The order of presentation of the references should not be constructed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, as a result of this submission to Deposit Account No. 502648, Reference No. 21402-235 (Cura 535).

Respectfully submitted,

Date: November 21, 2003

George Yahwak Reg. No. 26,824

c/o CuraGen Corporation

555 Long Wharf Drive New Haven, CT 06511

Tel: (203) 974-6303 Fax: (203) 401-3351

# Express Mail No. El#######US

Date of Deposit:

Please type a plus sign (+) in this box

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Application Number** 10/037,417 **Filing Date** 01/04/02 **First Named Inventor** Alsobrook, et al Group Art Unit 1631 **Examiner Name** Martinell, James Attorney Docket Number 21402-235 Cura 535

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1				-		

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.			Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	wo	01/77155	CuraGen Corporation	10/18/2001	x	
	B2	wo	01/83516	Massachusetts General Hospital	11/08/2001	х	
	В3	wo	01/98342	SmithKline Beecham Corporation	12/27/2001	х	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
	C163	Abts, H. F., T. Welss, et al. (1999). "Cloning and characterization of hurpin (protease inhibitor 13): A new skin-specific, UV-repressible serine proteinase inhibitor of the ovalbumin serpin family." J Mol Biol 293(1): 29-39.			
	C164	Chernova, O. B., R. P. Somerville, et al. (1998). "A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors." Oncogene 17(22): 2873-81.			
	C165	De Vivo, I., X. Cui, et al. (1998). "Growth stimulation of primary B cell precursors by the anti- phosphatase Sbf1." Proc Natl Acad Sci U S A 95(16): 9471-6.			
	C166	Durkin, M. E., F. Loechel, et al. (1997). "Tissue-specific expression of the human laminin alpha5-chain, and mapping of the gene to human chromosome 20q13.2-13.3 and to distal mouse chromosome 2 near the locus for the ragged (Ra) mutation." FEBS Lett 411(2-3): 296-300.			
	C167	Miner, J. H., et al., (1995) "Molecular cloning of a novel laminin chain, alpha-5, and widespread expression in adult mouse tissues." The Journal of Biological Chemistry 270 (48): 28523-26.			
	C168	Nagase, T., K. Ishikawa, et al. (1998). "Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro." DNA Res 5(1): 31-9.			
	C169	Pierce, R. A., G. L. Griffin, et al. (2000). "Expression patterns of laminin alpha1 and alpha5 in human lung during development." Am J Respir Cell Mol Biol 23(6): 742-7.			
	C170	Seebacher, T., J. L. Medina, et al. (1997). "Laminin alpha 5, a major transcript of normal and malignant rat liver epithelial cells, is differentially expressed in developing and adult liver." Exp Cell Res 237(1): 70-6.			
	C171	Yu, J. X., L. Chao, et al. (1995). "Molecular cloning, tissue-specific expression, and cellular localization of human prostasin mRNA." J Biol Chem 270(22): 13483-9.			
	C172	International Search Report of PCT/US/02/00375 mailed August 28, 2003.			

Express Mail No. EI########US Date of Deposit:	Page 2 of 2	i
a copy of this reference is not provided as it Serial No, filed	previously cited by or submitted to the office in a prior application, previously cited by or submitted to the office in a prior application, and divisional applications).	
Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRADOCS: 1177824.1 (p8tc01!.doc)